In the clinical context, PACAP has previously attracted attention because of its role as a potent trigger of migraine headaches, which has led to the exploration of strategies to antagonize the PACAP–PAC1 pathway as a potential new therapeutic approach for this significant neurological disorder.8, 11, 12. Here, ADCYAP1 is linked to nervous system disorder.